In emergencies, how do I find out whether the patient received Tranexamic acid or placebo?
• In general there should be no need to unblind the allocated treatment. If some contra-indication to tranexamic acid develops after randomisation (e.g. any clotting disorders), the trial treatment should simply be stopped. Unblinding should be done only in those rare cases when the doctor believes that clinical management depends importantly upon knowledge of whether the patient received tranexamic acid or placebo (e.g. anaphylaxis). In those few cases when urgent unblinding is considered necessary, the randomisation service should be telephoned, giving the name of the doctor requesting unblinding and the CRASH-2 treatment pack number. The caller will then be put in contact with a member of the trial team who will assist with unblinding.
